Based on the SYCAMORE trial [9] adalimumab is the only EMA and FDA approved biological agent for paediatric anterior NIU in patients from 2 years of age and currently considered the most efficacious anti-TNFα agent for childhood idiopathic or JIA associated NIU [5]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.